BioCatalystWatch
COCPWorkspace / COCP / OverviewCompany library
Cocrystal Pharma, Inc. logo

Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. (COCP)

Website

Price
Market cap
Next catalystPreliminary results near the end of 2026 or early 2027CDI-988 — Phase 1b norovirus human challenge study · Phase 1 dataCompany release ↗
Cash

Chart & Events

Candle interval

Core Clinical

CDI-988

Norovirus 3CL protease × Coronavirus 3CL protease

PreINDP1P2P3FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

CDI-988

Norovirus 3CL protease × Coronavirus 3CL protease

PreINDP1P2P3FilingApproved
Upcoming / outlook

Other pipelines

CDI-988

Norovirus 3CL protease × Coronavirus 3CL protease

PreINDP1P2P3FilingApproved

History / paused

CDI-988

Norovirus 3CL protease × Coronavirus 3CL protease

PreINDP1P2P3FilingApproved

Financial position

Short-term investments

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

COCP PR & News

PR & News

COCP SEC archive